Advertisement

Current Dermatology Reports

, Volume 8, Issue 4, pp 297–302 | Cite as

Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update

  • Nina M. FischerEmail author
  • Ralf S. Müller
Veterinary Dermatology (A Rostaher and N Fischer)
  • 21 Downloads
Part of the following topical collections:
  1. Topical Collection on Veterinary Dermatology

Abstract

Purpose of Review

This review aims to evaluate new insights into allergen immunotherapy (AIT) and review the mechanism, different protocols used, and response rate of this treatment option for canine atopic dermatitis.

Recent Findings

AIT is the only etiological treatment available for canine atopic dermatitis. Selection of allergens is based on clinical history in conjunction with positive reactions on intradermal and serum testing. During decades AIT was applied subcutaneously (SCIT) using aqueous or aluminum-precipitated solution of allergens, but in the last few years, new routes like sublingual (SLIT), intralymphatic (ILIT), and epicutaneous administration are on the rise. AIT combines a satisfactory success rate (around 70%) with a good safety profile. Adverse effects include mainly increased pruritus and anaphylactic reactions are rarely seen in animals. Pilot studies with different adjuvants to further increase safety and efficacy have been published.

Summary

AIT is a safe and effective therapy for canine atopic dermatitis. However, as most of the published studies are case series with often rather small numbers of animals included, more and larger randomized studies of immunotherapy are needed in a clinical setting to provide guidance on the optimal selection of allergens, adjuvants, dosing, success rate, and adverse effects of the various protocols of immunotherapy in dogs.

Keywords

Allergen specific Desensitization Hyposensitization Feline Canine Intralymphatic 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Nina Fischer received a grant for an immunotherapy study from Albertheim Stiftung und Waltham.

Dr. Ralf Müller received financial support for studies about immunotherapy from Greer Laboratories, Artu Biologicals, and Heska Laboratories.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol. 2006;114(3–4):207–8.  https://doi.org/10.1016/j.vetimm.2006.08.013.CrossRefPubMedGoogle Scholar
  2. 2.
    Marsella R, Sousa CA, Gonzales AJ, Fadok VA. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. J Am Vet Med Assoc. 2012;241(2):194–207.  https://doi.org/10.2460/javma.241.2.194.CrossRefPubMedGoogle Scholar
  3. 3.
    Nuttall T, Uri M, Halliwell R. Canine atopic dermatitis- what have we learned? Vet Rec. 2013;172(8):201–7.  https://doi.org/10.1136/vr.f1134.CrossRefPubMedGoogle Scholar
  4. 4.
    Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 2001;81:363–84.CrossRefGoogle Scholar
  5. 5.
    Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol. 2009;20(2):84–98.  https://doi.org/10.1111/j.1365-3164.2008.00727.x.CrossRefPubMedGoogle Scholar
  6. 6.
    Maggi E. T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol. 2010;161(1):10–8.  https://doi.org/10.1111/j.1365-2249.2010.04148.x.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    •• Mueller RS, Jensen-Jarolim E, Roth-Walter F, Marti E, Janda J, Seida AA, et al. Allergen immunotherapy in people, dogs, cats and horses - differences, similarities and research needs. Allergy. 2018;73(10):1989–99.  https://doi.org/10.1111/all.13464High level review article on immunotherapy in animals and humans. Very up to date information on all imprortant aspects of immunotherapy in all species. CrossRefPubMedGoogle Scholar
  8. 8.
    Willemse A, van den Brom WE, Rijnberg A. Effect of hyposensitization on atopic dermatitis in dogs. J Am Vet Med Assn. 1984;184:1277–80.Google Scholar
  9. 9.
    Schnabl B, Bettenay SV, Dow K, Mueller RS. Results of allergen-specific immunotherapy in 117 dogs with atopic dermatitis. Vet Rec. 2006;158(3):81–5.CrossRefGoogle Scholar
  10. 10.
    Mueller RSFK, Zabel S, Rosychuk RAW. Conventional and rush immunotherapy in canine atopic dermatitis. In: Hillier A, Foster AP, Kwochka KW, editors. Advances in veterinary dermatology. Oxford: Blackwell Publishing; 2005. p. 60–9.Google Scholar
  11. 11.
    • Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127(1):18–27.  https://doi.org/10.1016/j.jaci.2010.11.030 quiz 8–9. Review article, which sums up the suspected mechanism of AIT. CrossRefPubMedGoogle Scholar
  12. 12.
    Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–68.  https://doi.org/10.1016/j.jaci.2015.04.047.CrossRefPubMedGoogle Scholar
  13. 13.
    Jutel M, Kosowska A, Smolinska S. Allergen immunotherapy: past, present, and future. Allergy, Asthma Immunol Res. 2016;8(3):191–7.  https://doi.org/10.4168/aair.2016.8.3.191.CrossRefGoogle Scholar
  14. 14.
    DeBoer DJ, Verbrugge M, Morris M. Clinical and immunological responses of dust mite sensitive, atopic dogs to treatment with sublingual immunotherapy (SLIT). Vet Dermatol. 2016;27:82–e24.  https://doi.org/10.1111/vde.12284.CrossRefPubMedGoogle Scholar
  15. 15.
    Ozmen I, Marsella R. Sublingual immunotherapy in human and canine atopic dermatitis: a mini review. Vet. Sci. 2014, 1(3), 136-149CrossRefGoogle Scholar
  16. 16.
    Hatzmann KMR. Practicability and safety of intralymphatic allergen-specific immunotherapy in dogs with atopic dermatitis. J Vet Dermatol. 2011;22: 463-464 (Abstract).Google Scholar
  17. 17.
    • Fischer N, Rostaher A, Favrot C. Intralymphatic immunotherapy: an effective and safe alternative route for canine atopic dermatitis. Schweiz Arch Tierheilkd. 2016;158(9):646–52.  https://doi.org/10.17236/sat00085Up to date study on the efficacy and safety of intralymphatic immunotherapy in dogs. CrossRefPubMedGoogle Scholar
  18. 18.
    Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129(1):128–35.  https://doi.org/10.1016/j.jaci.2011.08.036.CrossRefPubMedGoogle Scholar
  19. 19.
    •• Mueller RS, Janda J, Jensen-Jarolim E, Rhyner C, Marti E. Allergens in veterinary medicine. Allergy. 2016;71(1):27–35.  https://doi.org/10.1111/all.12726High level and up to date review about allergens and allergy testing in veterinary medicine. CrossRefPubMedGoogle Scholar
  20. 20.
    • Fischer N, Tarpataki N, Leidi F, Rostaher A, Favrot C. An open study on the efficacy of a recombinant Der f 2 (Dermatophagoides farinae) immunotherapy in atopic dogs in Hungary and Switzerland. Vet Dermatol. 2018;29:337–e118.  https://doi.org/10.1111/vde.12657. Up to date study on the efficacy and safety of the first recombinant immunotherapy use in dogs. CrossRefGoogle Scholar
  21. 21.
    • Kawano K, Mizuno T. A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis. Vet Dermatol. 2017;28(6):583–e141.  https://doi.org/10.1111/vde.12470Up to date study on the efficacy and safety of the first recombinant immunotherapy use in dogs. CrossRefPubMedGoogle Scholar
  22. 22.
    Sahin E, Bafaqeeh SA, Guven SG, Cetinkaya EA, Muluk NB, Coskun ZO, et al. Mechanism of action of allergen immunotherapy. Am J Rhinol Allergy. 2016;30(5):1–3.  https://doi.org/10.2500/ajra.2016.30.4367.CrossRefPubMedGoogle Scholar
  23. 23.
    Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–31.  https://doi.org/10.1016/j.jaci.2013.12.1088.CrossRefPubMedGoogle Scholar
  24. 24.
    Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17.  https://doi.org/10.1186/s40413-015-0063-2.CrossRefPubMedGoogle Scholar
  25. 25.
    Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int. 2013;62(4):425–33.  https://doi.org/10.2332/allergolint.13-RAI-0608.CrossRefPubMedGoogle Scholar
  26. 26.
    Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest. 1976;57(5):1378–85.  https://doi.org/10.1172/JCI108406.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Till SJ, Durham SR. Immunological responses to allergen immunotherapy. Clin Allergy Immunol. 2004;18:85–104.PubMedGoogle Scholar
  28. 28.
    Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy. 1997;27(9):1007–15.CrossRefGoogle Scholar
  29. 29.
    Hou CC, Griffin CE, Hill PB. Dermatophagoides farinae-specific IgG responses in atopic dogs undergoing allergen-specific immunotherapy with aqueous vaccines. Vet Dermatol. 2008;19(4):215–20.CrossRefGoogle Scholar
  30. 30.
    Hites MJ, Kleinbeck ML, Loker JL, Lee KW. Effect of immunotherapy on the serum concentrations of allergen-specific IgG antibodies in dog sera. Vet Immunol Immunopathol. 1989;22(1):39–51.CrossRefGoogle Scholar
  31. 31.
    Keppel KE, Campbell KL, Zuckermann FA, Greeley EA, Schaeffer DJ, Husmann RJ. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy. Vet Immunol Immunopathol. 2008;123(3–4):337–44.  https://doi.org/10.1016/j.vetimm.2008.02.008.CrossRefPubMedGoogle Scholar
  32. 32.
    Lian TMHR. Allergen-specific IgE and IgG antibodies in atopic and normal dogs. Vet Immunol Immunopathol. 1998;66(3–4):203–23.CrossRefGoogle Scholar
  33. 33.
    Mueller RS, Fieseler KV, Rosychuk RA, Greenwalt T. Intradermal testing with the storage mite Tyrophagus putrescentiae in normal dogs and dogs with atopic dermatitis in Colorado. Vet Dermatol. 2005;16(1):27–31.  https://doi.org/10.1111/j.1365-3164.2005.00415.x.CrossRefPubMedGoogle Scholar
  34. 34.
    Gedon NKY, Boehm T, Klinger CJ, Udraite L, Mueller RS. Agreement of serum allergen test results with unblocked and blocked IgE against cross-reactive carbohydrate determinants (CCD) and intradermal test results in atopic dogs. Vet Dermatol. 2019;30(3):195–e61.  https://doi.org/10.1111/vde.12742.CrossRefPubMedGoogle Scholar
  35. 35.
    Willemse T, Bardagi M, Carlotti DN, Ferrer L, Fondati A, Fontaine J, et al. Dermatophagoides farinae-specific immunotherapy in atopic dogs with hypersensitivity to multiple allergens: a randomised, double blind, placebo-controlled study. Vet J. 2009;180(3):337–42.  https://doi.org/10.1016/j.tvjl.2008.01.004.CrossRefPubMedGoogle Scholar
  36. 36.
    Plant JD, Neradilek MB. Effectiveness of regionally-specific immunotherapy for the management of canine atopic dermatitis. BMC Vet Res. 2017;13(1):4–6.  https://doi.org/10.1186/s12917-016-0917-z.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Telia AA, Telia AZ, Machavariani K, Telia Z. Sublingual immunotherapy for allergic asthma and rhinitis. Georgian Med News. 2018;276:123–30.Google Scholar
  38. 38.
    Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med. 2008;14(5):191–8.  https://doi.org/10.1016/j.molmed.2008.03.001.CrossRefPubMedGoogle Scholar
  39. 39.
    • Timm K, Mueller RS, Nett-Mettler CS. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis. Vet Dermatol. 2018;29(2):123–e49.  https://doi.org/10.1111/vde.12517Up to date study on the efficacy and safety of intralymphatic immunotherapy in dogs. CrossRefPubMedGoogle Scholar
  40. 40.
    • Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–6.  https://doi.org/10.1016/j.jaci.2012.02.026This article is one of the first introducing intralymphatic immunotherapy. It’s a human study stating the advantages of fast efficacy and safety in comparison to subcutaneous immunotherapy. CrossRefPubMedGoogle Scholar
  41. 41.
    • Hobi S, Mueller RS. Efficacy and safety of rush immunotherapy with alum-precipitated allergens in canine atopic dermatitis. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014;42(3):167–73 An up to date study on rush immunotherapy used in veterinary dermatology. This study shows the advantages of this immunotherapy protocol. PubMedGoogle Scholar
  42. 42.
    Fujimura M, Ishimaru H. Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study. Pol J Vet Sci. 2016;19(1):3–6.  https://doi.org/10.1515/pjvs-2016-0001.CrossRefPubMedGoogle Scholar
  43. 43.
    Mueller RS, Bettenay SV. Evaluation of the safety of an abbreviated course of injections of allergen extracts (rush immunotherapy) for the treatment of dogs with atopic dermatitis. Am J Vet Res. 2001;62(3):307–10.CrossRefGoogle Scholar
  44. 44.
    Bozek A, Kolodziejczyk K. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy. Hum Vaccin Immunother. 2018;14(2):288–91.  https://doi.org/10.1080/21645515.2017.1397245.CrossRefPubMedGoogle Scholar
  45. 45.
    Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61(Suppl 82):1–20.  https://doi.org/10.1111/j.1398-9995.2006.01219_1.x.CrossRefPubMedGoogle Scholar
  46. 46.
    Uchida T, Ikegami H, Ando S, Kurimoto M, Mitsuhashi M, Naito S, et al. Suppression of murine IgE responses with ovalbumin-pullulan conjugates: comparison of the suppressive effect of different conjugation methods and different molecular weights of pullulan. Int Arch Allergy Immunol. 1993;102(3):276–8.CrossRefGoogle Scholar
  47. 47.
    Manzano AI, Javier Canada F, Cases B, Sirvent S, Soria I, Palomares O, et al. Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Glycoconj J. 2016;33(1):93–101.  https://doi.org/10.1007/s10719-015-9640-4.CrossRefPubMedGoogle Scholar
  48. 48.
    Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol. 2016;138(2):558–67 e11.  https://doi.org/10.1016/j.jaci.2016.02.029.CrossRefPubMedGoogle Scholar
  49. 49.
    Gonzalez JL, Zalve V, Fernandez-Caldas E, Cases B, Subiza JL, Casanovas M. A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan-Dermatophagoides farinae allergoid targeting dendritic cells. Vet Dermatol. 2018;29(5):449–e152.  https://doi.org/10.1111/vde.12679.CrossRefPubMedGoogle Scholar
  50. 50.
    Kolaczek A, Skorupa D, Antczak-Marczak M, Kuna P, Kupczyk M. Safety and efficacy of venom immunotherapy: a real life study. Postepy Dermatol Alergol. 2017;34(2):159–67.  https://doi.org/10.5114/ada.2017.67082.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992;89(2):529–35.  https://doi.org/10.1016/0091-6749(92)90319-w.CrossRefPubMedGoogle Scholar
  52. 52.
    Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010;126(1):105–11 e5.  https://doi.org/10.1016/j.jaci.2010.04.025.CrossRefPubMedGoogle Scholar
  53. 53.
    •• Mueller RS. Update on allergen immunotherapy. Vet Clin N Am-Small. 2019;49(1):1–7.  https://doi.org/10.1016/j.cvsm.2018.08.001. Review article on immunotherapy in animals. Very up to date information on all imprortant aspects of immunotherapy in cats and dogs. CrossRefGoogle Scholar
  54. 54.
    Shida M, Kadoya M, Park SJ, Nishifuji K, Momoi Y, Iwasaki T. Allergen-specific immunotherapy induces Th1 shift in dogs with atopic dermatitis. Vet Immunol Immunopathol. 2004;102(1–2):19–31.  https://doi.org/10.1016/j.vetimm.2004.06.003.CrossRefPubMedGoogle Scholar
  55. 55.
    • Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol. 2001;81(3–4):363–83 Although this review article is quiet old—it still serves as high importance since it’s the summerized opinion of leading dermatologists (ACVD taskt force) on the topic of immunotherapy. CrossRefGoogle Scholar
  56. 56.
    Scott DW. Observations on canine atopy. J Am Anim Hosp Assoc. 1981;17(1):91–100.Google Scholar
  57. 57.
    Marsella R, Ahrens K. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs. Vet Dermatol. 2018;29(5):439–e146.  https://doi.org/10.1111/vde.12660.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Dermatology Unit, Clinic for Small Animal Internal Medicine, Vetsuisse FacultyUniversity of ZurichZurichSwitzerland
  2. 2.Zentrum für klinische TiermedizinLMU MunichMunichGermany

Personalised recommendations